Discovery of a first-in-class reversible DNMT1-selective inhibitor

被引：0
|
作者：
Pappalardi, Melissa B. [1 ]
机构：
[1] GlaxoSmithKline, Collegeville, PA USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3265
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Discovery of a First-in-Class Protein Arginine Methyltransferase 6 (PRMT6) Covalent Inhibitor
    Shen, Yudao
    Li, Fengling
    Szewczyk, Magdalena M.
    Halabelian, Levon
    Park, Kwang-Su
    Chau, Irene
    Dong, Aiping
    Zeng, Hong
    Chen, He
    Meng, Fanye
    Barsyte-Lovejoy, Dalia
    Arrowsmith, Cheryl H.
    Brown, Peter J.
    Liu, Jing
    Vedadi, Masoud
    Jin, Jian
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (10) : 5477 - 5487
  • [42] Discovery of a First-in-Class Inhibitor of the Histone Methyltransferase SETD2 Suitable for Preclinical Studies
    Lampe, John W.
    Alford, Joshua S.
    Boriak-Sjodin, P. Ann
    Brach, Dorothy
    Cosmopoulos, Kat
    Duncan, Kenneth W.
    Eckley, Sean T.
    Foley, Megan A.
    Harvey, Darren M.
    Motwani, Vinny
    Munchhof, Michael J.
    Raimondi, Alejandra
    Riera, Thomas, V
    Tang, Cuyue
    Thomenius, Michael J.
    Totman, Jennifer
    Farrow, Neil A.
    ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (10): : 1539 - 1545
  • [43] Discovery of TAK-981, a first-in-class inhibitor of Sumo Activating Enzyme (SAE) in phase 1 clinical trials
    Langston, Steven
    England, Dylan
    He, Xingyue
    Huszar, Dennis
    Greenspan, Paul
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [44] The discovery and preclinical characterization of AMG 176: A first-in-class Mcl-1 inhibitor in clinical development for multiple myeloma
    Hughes, Paul E.
    CANCER RESEARCH, 2017, 77
  • [45] Discovery of a First-in-Class Degrader for the Lipid Kinase PIKfyve
    Li, Chungen
    Qiao, Yuanyuan
    Jiang, Xia
    Liu, Lianchao
    Zheng, Yang
    Qiu, Yudi
    Cheng, Caleb
    Zhou, Fengtao
    Zhou, Yang
    Huang, Weixue
    Ren, Xiaomei
    Wang, Yuzhuo
    Wang, Zhen
    Chinnaiyan, Arul M.
    Ding, Ke
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (17) : 12432 - 12445
  • [46] Discovery of the first-in-class potent and isoform-selective human carbonic anhydrase III inhibitors
    Giovannuzzi, Simone
    Bonardi, Alessandro
    Gratteri, Paola
    Nocentini, Alessio
    Supuran, Claudiu T. T.
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2023, 38 (01)
  • [47] Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor
    Hubbard, Joleen M.
    Grothey, Axel
    DRUGS, 2017, 77 (10) : 1091 - 1103
  • [48] Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor
    Joleen M. Hubbard
    Axel Grothey
    Drugs, 2017, 77 : 1091 - 1103
  • [49] Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase
    Choi, Eun-Ji
    BLOOD RESEARCH, 2023, 58 : 29 - 36
  • [50] A first-in-class EGFR-directed KRAS G12V selective inhibitor
    Stanland, Lyla
    Huggins, Hayden
    Porrello, Alessandro
    Chareddy, Yogitha
    Azam, Salma
    Perry, Jillian
    Pallan, Pradeep
    Whately, Kristina
    Edatt, Lincy
    Fleming, Matthew
    Im, Jonah
    Gutierrez-Ford, Christina
    Simmons, Imani
    Jayaprakash, Vandanaa
    Sellers, Rani
    de la Cruz, Gabriela
    Wielgus, Albert
    Egli, Martin
    Bowers, Albert
    Pecot, Chad
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (11)
12345